HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
flestolol
short-acting beta blockader
Also Known As:
ACC 9089; ACC-9089; flestolol sulfate
Networked:
11
relevant articles (
3
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amines: 4871
Amino Alcohols: 20
Propanolamines: 4
flestolol: 11
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Fluorobenzenes: 14
flestolol: 11
Halogenated Hydrocarbons: 42
Fluorinated Hydrocarbons: 4
Fluorobenzenes: 14
flestolol: 11
Alcohols: 595
Amino Alcohols: 20
Propanolamines: 4
flestolol: 11
Propanols: 3
Propanolamines: 4
flestolol: 11
Related Diseases
1.
Tachycardia (Tachyarrhythmias)
11/01/1987 - "
Flestolol prevented initiation of tachycardia by causing block in anterograde AV nodal conduction.
"
01/01/1986 - "
Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.
"
11/01/1986 - "
Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
"
01/01/1987 - "
The average maximum reduction in isoproterenol tachycardia was in the range of 63% to 79% during flestolol infusion.
"
05/01/1986 - "
A dose-dependent attenuation of isoproterenol-induced tachycardia and increase in systolic blood pressure occurred with flestolol at doses ranging from 0.5 to 15.0 micrograms/kg/min. The average percent reduction in isoproterenol-induced tachycardia (beta-blockade) at each dose of flestolol, 0.5, 2.5, 5.0, 15.0, and 50.0 micrograms/kg/min, was 15.1%, 45.9%, 67.0%, 85.9%, and 90.3%, respectively.
"
2.
Critical Illness (Critically Ill)
03/01/1988 - "
Thus flestolol, with its unique pharmacokinetic profile and titrability, may be beneficial in the treatment of critically ill patients.
"
02/01/1990 - "
Flestolol has an extremely short half-life, demonstrated by an 83% loss of effect within 25 min. Thus, flestolol allows easy titration of the effect, which might be a valuable property for its use in the treatment of critically ill patients.
"
3.
Atrial Fibrillation
11/01/1986 - "
Flestolol, a new ultrashort-acting (half-life 6.9 minutes) beta-blocking drug, was administered by intravenous infusion to 18 patients with new-onset atrial fibrillation or flutter and rapid ventricular response (120 beats/min or more for at least 30 minutes).
"
07/01/1988 - "
The ultrashort-acting beta blocker flestolol was studied during atrial pacing and atrial fibrillation (AF) in 10 patients with Wolff-Parkinson-White syndrome.
"
07/01/1988 - "
Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
"
11/01/1986 - "
Flestolol is effective in slowing ventricular response in new-onset atrial fibrillation and flutter, maintains a therapeutic effect during continuous infusion and rapidly loses therapeutic effect when discontinued.
"
4.
Chest Pain (Chest Pains)
01/01/1986 - "
In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.
"
5.
Unstable Angina
01/01/1986 - "
In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.
"
Related Drugs and Biologics
1.
Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)
2.
Therapeutic Uses
3.
Isoproterenol (Isoprenaline)
4.
Milrinone (Primacor)
5.
Enoximone
6.
Propafenone (Rythmol)
7.
Pentobarbital (Nembutal)
8.
Ouabain (G Strophanthin)
9.
Norepinephrine (Noradrenaline)
10.
Anti-Arrhythmia Agents
Related Therapies and Procedures
1.
Intravenous Infusions
2.
Controlled Hypotension